Hikma Ramipril Capsules 10mg Recall: Impurity Risk
Hikma Pharmaceuticals recalls 10mg Ramipril capsules due to failed impurities test. Products may contain dicyclohexylurea (DCU) which could cause harm. Check NDC codes 76282-673-01 or 76282-673-05 for affected lots.
Recall notice
Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
What happened, in plain English
Hikma Pharmaceuticals is recalling 10mg Ramipril capsules that failed impurity testing. The capsules may contain dicyclohexylurea (DCU), a chemical that could cause harm if taken. This recall affects specific packaging sizes and lots. Read more at govinfonow.com/recall/692845-hikma-ramipril-capsules-10mg-recall-impurity-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/692845-hikma-ramipril-capsules-10mg-recall-impurity-risk · Updated September 14, 2026 · FDA enforcement record: FDA #D-0831-2026
Cite this page
“Hikma Ramipril Capsules 10mg Recall: Impurity Risk.” GovInfoNow, updated September 14, 2026. https://govinfonow.com/recall/692845-hikma-ramipril-capsules-10mg-recall-impurity-risk. Based on FDA recall #D-0831-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0831-2026%22&limit=1).
Why it’s dangerous
The capsules failed a test for a chemical called dicyclohexylurea (DCU). This impurity could be harmful if taken, but the exact risk level isn't specified in the recall notice.
Who’s affected
People who have the 100-capsule or 500-capsule packages with NDC codes 76282-673-01 or 76282-673-05. Those taking Ramipril for blood pressure or heart conditions are most at risk.
How to tell if you have this one
Check for NDC codes 76282-673-01 (100 capsules) or 76282-673-05 (500 capsules). The products were manufactured in specific lots (AC5470A or AC5470B) with expiration dates of July 2027.
- Brand
Hikma Pharmaceuticals- Category
Drug
What to do — step by step
Check Product Details
Look for NDC codes 76282-673-01 or 76282-673-05 on the packaging.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 9 days after the firm started it.
- Firm started the recall
- Published in FDA’s Enforcement Report
- FDA classified it Class II
- Added to GovInfoNow
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Hikma Pharmaceuticals recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0831-2026 (August 24, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0831-2026 to see it in context.
- Plain-language summary written by qwen3:4b on September 14, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.